Irvine Scientific introduces medium for large-scale transient transfection
The new medium is chemically-defined, animal component free, and has been specifically designed to support sustained, high growth with increased transfection efficiency that can yield gram-scale protein expression.
Irvine Scientific has released BalanCD Transfectory CHO, a cell culture medium for rapid, scalable production of recombinant proteins through transient transfection in CHO cells. The new medium is chemically-defined, animal component free, and has been specifically designed to support sustained, high growth with increased transfection efficiency that can yield gram-scale protein expression.
Transient gene expression (TGE) has evolved into a cost-effective, rapid alternative to stable cell line engineering for the production of recombinant proteins and antibodies needed for early-stage biopharmaceutical development activities. CHO cells are the most prevalent platform used for commercial production of biopharmaceuticals, they are therefore viewed as preferential hosts for TGE. The challenge, however, has been in obtaining protein yield of sufficient quantity and quality, leading many scientists to focus on 293HEK transfection. The ability to obtain gram-scale yields by transient transfection in CHO cells is a real step forward towards cutting costs and development time for biotherapeutic research.
Commenting on this latest addition to the BalanCD portfolio, Dr Jessie Ni, Chief Scientific Officer at Irvine Scientific, said: “Our goal is to provide a platform of chemically-defined and animal-derived component free formulas designed to produce high yields, while maintaining protein quality through every phase of development and at all production scales. The addition of BalanCD Transfectory CHO extends the capability of the BalanCD portfolio, thus enabling scientists to produce the proteins needed to assess candidates using rapid and cost effective methods.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance